title: [Therapeutic effects of imipenem/cilastatin sodium against severe infections in patients with hematopoietic disorders. Hanshin Infection Study Group].
abstract: One hundred ninety-eight patients with severe infections associated with hematopoietic disorders were treated with imipenem/cilastatin sodium (IPM/CS), and the efficacy and safety of the drug were evaluated. The results obtained are summarized below. 1. Out of 182 patients in whom efficacies are evaluable, responses were excellent in 50 patients, good in 52, fair in 21 and poor in 59, and the efficacy rating was 56.0%. 2. The efficacy rating in 87 patients who had failed to respond to prior treatment with other antibiotics was 58.6%. 3. There were significant differences in efficacy ratings when patients were grouped according to differences the number of neutrophils after treatment, less than 100, 101 approximately 500 and over 501/mm3. 4. The eradication rate in 38 patients from whom causative organisms were isolated was 75.8%. 5. Out of 197 patients in whom the safety was evaluable, side effects were observed in 19 patients (9.6%) and abnormal laboratory test values in 15 (7.6%).
authors.affiliation: Department of Laboratory Medicine, Osaka City University Medical School.
authors.forename: N
authors.initials: N
authors.lastname: Tatsumi
authors.forename: T
authors.initials: T
authors.lastname: Nin
authors.forename: Y
authors.initials: Y
authors.lastname: Sannomiya
authors.forename: T
authors.initials: T
authors.lastname: Kageyama
authors.forename: H
authors.initials: H
authors.lastname: Ohyabu
authors.forename: K
authors.initials: K
authors.lastname: Akasaka
authors.forename: K
authors.initials: K
authors.lastname: Nasu
authors.forename: T
authors.initials: T
authors.lastname: Yonezawa
authors.forename: N
authors.initials: N
authors.lastname: Tominaga
authors.forename: T
authors.initials: T
authors.lastname: Kitani
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000209:etiology; D015377:Cilastatin / Q000008:administration & dosage / Q000627:therapeutic use*; D000077728:Cilastatin, Imipenem Drug Combination; D002986:Clinical Trials as Topic; D004338:Drug Combinations / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D015378:Imipenem / Q000008:administration & dosage / Q000627:therapeutic use*; D007262:Infusions, Intravenous; D015470:Leukemia, Myeloid, Acute / Q000150:complications*; D007958:Leukocyte Count; D008223:Lymphoma / Q000150:complications*; D008297:Male; D008875:Middle Aged
chemical_list: D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D015377:Cilastatin; D015378:Imipenem; D000077728:Cilastatin, Imipenem Drug Combination